ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/ hyperactivity disorder in children and adolescents

Pediatrics

Volumn 128, Issue 5, 2011, Pages 1007-1022

  Wolraich, Mark ^a   Brown, Lawrence ^b   Brown, Ronald T ^c   DuPaul, George ^d   Earls, Marian ^a   Feldman, Heidi M ^e   Ganiats, Theodore G ^f   Kaplanek, Beth ^a   Meyer, Bruce ^a   Perrin, James ^g   Pierce, Karen ^h   Reiff, Michael ⁱ   Stein, Martin T ⁱ   Visser, Susanna ^a   Capers, Melissa ^a   Davidson, Caryn ^a  

^a Shire Eli Lilly Shinogi and Next Wave Pharmaceuticals ^*

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Society for Pediatric Psychology   (United States)

^d National Association of School Psychologists   (United States)

^e Society for Developmental and Behavioral Pediatricians   (United States)

^f AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

^g AAP Mental Health Task Force   (United States)

^h American Academy of Child and Adolescent Psychiatry   (United States)

ⁱ AAP Section on Developmental and Behavioral Pediatrics   (United States)

Author keywords

Adolescents; Attention deficit hyperactivity disorder; Behavioral therapy; Children; Medication; Preschool

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; GUANFACINE; METHYLPHENIDATE;

ABDOMINAL PAIN; ACADEMIC ACHIEVEMENT; ADOLESCENT; ADVERSE OUTCOME; AGE DISTRIBUTION; ANOREXIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; BEHAVIOR DISORDER; BEHAVIOR THEORY; CHILD; CHILD CARE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; COMORBIDITY; CONDUCT DISORDER; DELAYED DIAGNOSIS; DEPRESSION; DEVELOPMENTAL DISORDER; DISEASE COURSE; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; EMOTIONAL DISORDER; ENVIRONMENTAL FACTOR; EVIDENCE BASED PRACTICE; GASTROINTESTINAL DISEASE; GENERAL PRACTITIONER; HALLUCINATION; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HEART DEATH; HUMAN; HYPERACTIVITY; HYPERTROPHIC CARDIOMYOPATHY; IMPULSIVENESS; LANGUAGE DISABILITY; LEARNING DISORDER; LONG QT SYNDROME; MEDICAL INFORMATION; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; NEUROLOGIC DISEASE; OPPOSITIONAL DEFIANT DISORDER; PHYSICAL DISEASE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; REBOUND; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SOCIAL INTERACTION; SOMNOLENCE; SUDDEN DEATH; SUICIDAL IDEATION; TIC; TOXIC HEPATITIS; TREATMENT PLANNING; TREND STUDY; WELLBEING; WOLFF PARKINSON WHITE SYNDROME; XEROSTOMIA;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; FEMALE; GUIDELINE ADHERENCE; HUMANS; INCIDENCE; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 80355130491     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-2654     Document Type: Review

References (70)

1. American Academy of Pediatrics, Committee on Quality Improvement and Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. Pediatrics. 2000;105(5):1158-1170
2. American Academy of Pediatrics, Subcommittee on Attention-Deficit/ Hyperactivity Disorder, Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attentiondeficit/ hyperactivity disorder. Pediatrics. 2001;108(4):1033-1044
3. Wolraich ML, Felice ME, Drotar DD. The Classification of Child and Adolescent Mental Conditions in Primary Care: Diagnostic and Statistical Manual for Primary Care (DSM-PC), Child and Adolescent Version. Elk Grove, IL: American Academy of Pediatrics; 1996
4. EndNote [computer program]. 10th ed. Carlsbad, CA: Thompson Reuters; 2009
5. Charach A, Dashti B, Carson P, Booker L, Lim CG, Lillie E, Yeung E, Ma J, Raina P, Schachar R. Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment. Comparative Effectiveness Review No. 44. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. MME2202 290-02-0020.) AHRQ Publication No. 12-EHC003-EF. Rockville, MD: Agency for Healthcare Research and Quality. October 2011.
6. American Academy of Pediatrics, Steering Committee on Quality Improvement. Classifying recommendations for clinical practice guidelines. Pediatrics. 2004;114(3):874-877
7. Foy JM; American Academy of Pediatrics Task Force on Mental Health. Enhancing pediatric mental health care: report from the American Academy of Pediatrics Task Force on Mental Health. Introduction. Pediatrics. 2010;125(suppl 3)S69-S174
8. Visser SN, Lesesne CA, Perou R. National estimates and factors associated with medication treatment for childhoodattention-deficit/hyperactivity disorder. Pediatrics. 2007;119(suppl 1):S99-S106 (Pubitemid 46397953)
9. Centers for Disease Control and Prevention. Mental health in the United States: prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder - United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;54(34):842-847
10. Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention deficit/hyperactivity disorder among children: United States, 2003-2007. MMWR Morb Mortal Wkly Rep. 2010;59(44):1439-1443
11. Egger HL, Kondo D, Angold A. The epidemiology and diagnostic issues in preschool attention-deficit/hyperactivity disorder. Infant Young Child. 2006;19(2):109-122 (Pubitemid 44510368)
12. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/ hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics. 2005;115(6):1734-1746 (Pubitemid 43843185)
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000
14. American Psychiatric Association. Diagnostic criteria for attention deficit/hyperactivity disorder. Available at: www.dsm5.org/ProposedRevision/ Pages/proposedrevision.aspx?rid=383. Accessed September 30, 2011
15. Lahey BB, Pelham WE, Stein MA, et al. Validity of DSM-IV attention-deficit/hyperactivity disorder for younger children [published correction appears in J Am Acad Child Adolesc Psychiatry. 1999;38(2):222]. J Am Acad Child Adolesc Psychiatry. 1998;37(7):695-702 (Pubitemid 28304532)
16. Pavuluri MN, Luk SL, McGee R. Parent reported preschool attention deficit hyperactivity: measurement and validity. Eur Child Adolesc Psychiatry. 1999;8(2):126-133 (Pubitemid 29327332)
17. Harvey EA, Youngwirth SD, Thakar DA, Errazuriz PA. Predicting attention-deficit/hyperactivity disorder and oppositional defiant disorder from preschool diagnostic assessments. J Consult Clin Psychol. 2009;77(2):349-354
18. Keenan K, Wakschlag LS. More than the terrible twos: the nature and severity of behavior problems in clinic-referred preschool children. J Abnorm Child Psychol. 2000;28(1):33-46 (Pubitemid 30179911)
19. Gadow KD, Nolan EE, Litcher L, et al. Comparison of attention-deficit/ hyperactivity disorder symptoms subtypes in Ukrainian schoolchildren. J Am Acad Child Adolesc Psychiatry. 2000;39(12):1520-1527
20. Sprafkin J, Volpe RJ, Gadow KD, Nolan EE, Kelly K. A DSM-IV-referenced screening instrument for preschool children: the Early Childhood Inventory-4. J Am Acad Child Adolesc Psychiatry. 2002;41(5):604-612 (Pubitemid 38338139)
21. Poblano A, Romero E. ECI-4 screening of attention deficit-hyperactivity disorder and co-morbidity in Mexican preschool children: preliminary results. Arq Neuropsiquiatr. 2006;64(4):932-936 (Pubitemid 46120158)
22. McGoey KE, DuPaul GJ, Haley E, Shelton TL. Parent and teacher ratings of attentiondeficit/hyperactivity disorder in preschool: the ADHD Rating Scale-IV Preschool Version. J Psychopathol Behav Assess. 2007;29(4):269-276 (Pubitemid 350165361)
23. Young J. Common comorbidities seen in adolescents with attention-deficit/hyperactivity disorder. Adolesc Med State Art Rev. 2008;19(2):216-228, vii
24. Freeman R; Tourette Syndrome International Database Consortium. Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome [published correction appears in Eur Child Adolesc Psychiatry. 2007;16(8):536]. Eur Child Adolesc Psychiatry. 2007;16(1 suppl):15-23
25. Riggs P. Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry. 1998;37(3):331-332 (Pubitemid 28101232)
26. Kratochvil CJ, Vaughan BS, Stoner JA, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics. 2011;127(4). Available at: www.pediatrics.org/cgi/content/full/127/4/e862
27. Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002;8(3):162-170 (Pubitemid 36378158)
28. Cuffe SP, Moore CG, McKeown RE. Prevalence and correlates of ADHD symptoms in the national health interview survey. J Atten Disord. 2005;9(2):392- 401
29. Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat 10. 2008;(237):1-14
30. Biederman J, Faraone SV, Wozniak J, Mick E, Kwon A, Aleardi M. Further evidence of unique developmental phenotypic correlates of pediatric bipolar disorder: findings from a large sample of clinically referred preadolescent children assessed over the last 7 years. J Affect Disord. 2004;82(suppl 1):S45-S58 (Pubitemid 39574983)
31. Biederman J, Kwon A, Aleardi M. Absence of gender effects on attention deficit hyperactivity disorder: findings in nonreferred subjects. Am J Psychiatry. 2005;162(6):1083-1089 (Pubitemid 40770690)
32. Biederman J, Ball SW, Monuteaux MC, et al. New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry. 2008;47(4):426-434 (Pubitemid 351450742)
33. Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A. Long-term, openlabel extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047-1055
34. Crabtree VM, Ivanenko A, Gozal D. Clinical and parental assessment of sleep in children with attention-deficit/hyperactivity disorder referred to a pediatric sleep medicine center. Clin Pediatr (Phila). 2003;42(9):807-813 (Pubitemid 37486846)
35. LeBourgeois MK, Avis K, Mixon M, Olmi J, Harsh J. Snoring, sleep quality, and sleepiness across attention-deficit/hyperactivity disorder subtypes. Sleep. 2004;27(3):520-525 (Pubitemid 44138816)
36. Chan E, Zhan C, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch Pediatr Adolesc Med. 2002;156(5):504-511 (Pubitemid 34492585)
37. Newcorn JH, Miller SR, Ivanova I, et al. Adolescent outcome of ADHD: impact of childhood conduct and anxiety disorders. CNS Spectr. 2004;9(9):668-678 (Pubitemid 39299239)
38. Sung V, Hiscock H, Sciberras E, Efron D. Sleep problems in children with attention-deficit/hyperactivity disorder: prevalence and the effect on the child and family. Arch Pediatr Adolesc Med. 2008;162(4):336-342 (Pubitemid 351519856)
39. American Academy of Pediatrics, Task Force on Mental Health. Addressing Mental Health Concerns in Primary Care: A Clinician's Toolkit [CD-ROM]. Elk Grove Village, IL: American Academy of Pediatrics; 2010
40. American Academy of Pediatrics, Committee on Child Health Financing. Scope of health care benefits for children from birth through age 26. Pediatrics. 2012; In press
41. Brito A, Grant R, Overholt S, et al. The enhanced medical home: the pediatric standard of care for medically underserved children. Adv Pediatr. 2008;55:9-28
42. Homer C, Klatka K, Romm D, et al. A review of the evidence for the medical home for children with special health care needs. Pediatrics. 2008;122(4). Available at: www.pediatrics.org/cgi/content/full/122/4/e922
43. Ingram S, Hechtman L, Morgenstern G. Outcome issues in ADHD: adolescent and adult long-term outcome. Ment Retard Dev Disabil Res Rev. 1999;5(3):243-250 (Pubitemid 29407210)
44. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Modifiers of longterm school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr. 2007;28(4):274-287 (Pubitemid 47256030)
45. Cheng JY, Cheng RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta- analysis and metaregression analysis. Psychopharmacology. 2007;194(2):197-209 (Pubitemid 47457955)
46. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil CJ. Once daily atomoxetine treatment for children and adolescents with ADHD: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896-1901 (Pubitemid 35283256)
47. Biederman J, Melmed RD, Patel A, et al.; SPD503 Study Group. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1). Availableat: www.pediatrics.org/cgi/content/ full/121/1/e73
48. Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215-226
49. Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(2):171-179
50. Newcorn J, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721-730 (Pubitemid 351810541)
51. Swanson J, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015-1027 (Pubitemid 47224817)
52. Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics. 2009;123(2):611-616
53. Avigan M. Review of AERS Data From Marketed Safety Experience During Stimulant Therapy: Death, Sudden Death, Cardiovascular SAEs (Including Stroke). Silver Spring, MD: Food and Drug Administration, Center for Drug Evaluation and Research; 2004. Report No. D030403
54. Perrin JM, Friedman RA, Knilans TK, et al. American Academy of Pediatrics, Black Box Working Group, Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/ hyperactivity disorder. Pediatrics. 2008;122(2):451-453
55. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009;32(11):1089-1110
56. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009;166(9):992-1001
57. Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1284- 1293 (Pubitemid 44665445)
58. Low K, Gendaszek AE. Illicit use of psycho-stimulants among college students: a preliminary study. Psychol Health Med. 2002;7(3):283-287
59. Cox D, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006;118(3). Available at: www.pediatrics.org/cgi/content/full/118/3/e704
60. Pelham W, Wheeler T, Chronis A. Empirically supported psychological treatments for attention deficit hyperactivity disorder. J Clin Child Psychol. 1998;27(2):190-205
61. Sonuga-Barke E, Daley D, Thompson M, Laver-Bradbury C,Weeks A. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. J Am Acad Child Adolesc Psychiatry. 2001;40(4):402-408 (Pubitemid 32242523)
62. Pelham W, Fabiano GA. Evidence-based psychosocial treatments for attention-deficit/ hyperactivity disorder. J Clin Child Adolesc Psychol. 2008;37(1):184-214
63. Van Cleave J, Leslie LK. Approaching ADHD as a chronic condition: implications for long-term adherence. J Psychosoc Nurs Ment Health Serv. 2008;46(8):28-36
64. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children With ADHD. Arch Gen Psychiatry. 1999;56(12):1073- 1086
65. Jensen P, Hinshaw SP, Swanson JM, et al. Findings from the NIMH multimodal treatment study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr. 2001;22(1):60-73 (Pubitemid 33040478)
66. Pelham WE, Gnagy EM. Psychosocial and combined treatments for ADHD. Ment Retard Dev Disabil Res Rev. 1999;5(3):225-236 (Pubitemid 29407208)
67. Davila RR, Williams ML, MacDonald JT. Memorandum on clarification of policy to address the needs of children with attention deficit disorders within general and/or special education. In: Parker HCThe ADD Hyperactivity Handbook for Schools. Plantation, FL: Impact Publications Inc; 1991:261-268
68. The College Board. Services for Students With Disabilities (SSD). Available at: www.collegeboard.com/ssd/student. Accessed July 8, 2011
69. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA 2002;288:1775-1779
70. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA 2002;288:1909-1914 (Pubitemid 35168149)